

# DRI® Gravity-Detect® Test

**IVD** For In Vitro Diagnostic Use

**REF** 10018532 (6 x 18 mL Kit)  
1194 (2 x 500 mL Kit)  
1754 Low Gravity Calibrator  
1755 High Gravity Calibrator  
1756 Level 1 Gravity Control  
1757 Level 2 Gravity Control

## Intended Use

The DRI® Gravity-Detect® Test is intended for the quantitative determination of human urine specific gravity.

## Summary and Explanation of the Test

A complete urine drug of abuse testing program normally involves specimen collection, initial screening with an immunoassay, followed by a confirmation test, such as gas chromatography/mass spectrometry (GC/MS), for positive samples.<sup>1</sup> Many drug users attempt to evade detection by adulterating their specimen in order to produce false negative results during the initial immunoassay screening. Adulteration methods include dilution with water, substitution with a drug free liquid, addition of readily available household materials (e.g., vinegar, baking soda, liquid drain opener, detergent, etc.) or tampering with certain chemicals (e.g., Urine-Aid, which contains glutaraldehyde, or Klear, which contains potassium nitrite).

Several methods have been used to detect urine adulteration. These methods include measuring the temperature, pH, specific gravity and creatinine concentration of the sample. Fresh normal urine should have the following typical characteristics: temperature between 32.5-37.7°C or 90.5-99.8°F,<sup>1</sup> pH within 4.7-7.8,<sup>2,3</sup> specific gravity within a range of 1.003-1.035 g/mL<sup>2,4,5</sup> and creatinine concentration of 80-200 mg/dL.<sup>5,9</sup> If any of these urine parameters is outside the specified range, there should be reason to believe that the urine sample has been adulterated.

Urine specific gravity measurement as well as other methods, such as measuring the concentration of creatinine, pH and appearance, are useful adjuncts to drugs of abuse testing in determining possible adulteration. Densitometer measurement, dipsticks or other manual methods can determine urine specific gravity. An end-point colorimetric measuring technique based on ionic strength measurement can also be used.

The DRI Gravity-Detect Test can be performed on automated clinical chemistry analyzers. This method is based on a linear relationship between the urine chloride ion concentration and the specific gravity.<sup>9</sup> The chloride ion concentration is determined colorimetrically using ferric perchlorate according to the following equation:



Chloride ion and ferric perchlorate in an acidic medium form a  $\text{FeCl}^{2+}$  complex with an absorbance maximum at 340 nm. The absorbance at 340 nm is directly proportional to the urine chloride concentration. A linear two-point calibration curve can be established and the sample urine specific gravity value can be extrapolated from the calibration curve using the corresponding absorbance result.

## Reagents

**Gravity-Detect Reagent:** Contains ferric perchlorate in an aqueous acidic solution.

### Additional Materials Required (sold separately):

**Low Specific Gravity Calibrator:** Contains an aqueous sodium chloride solution with a specific gravity of 1.010 g/mL.

**High Specific Gravity Calibrator:** Contains an aqueous sodium chloride solution with a specific gravity of 1.025 g/mL.

**Level 1 Specific Gravity Control:** Contains an aqueous sodium chloride solution with a specific gravity of 1.015 g/mL.

**Level 2 Specific Gravity Control:** Contains an aqueous sodium chloride solution with a specific gravity of 1.030 g/mL.

## ⚠ Precautions and Warning

**DANGER:** Gravity-Detect Test contains ≤4.0% Perchloric acid and ≤2.0% Iron (III) Perchlorate.

H318 - Causes serious eye damage.

H315 - Causes skin irritation.

H272 - May intensify fire; oxidizer.

Keep away from heat/sparks/open flames/hot surfaces - No smoking. Keep/Store away from clothing/combustible materials. Take any precaution to avoid mixing with combustibles. Wash hands thoroughly after handling. Wear protective gloves/eye protection/face protection. Specific treatment (see First Aid information on product label and/or Section 4 of the SDS). If on skin: Wash with plenty of soap and water. IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. Immediately call a Poison Center or doctor/physician. If skin irritation occurs: Get medical advice/attention. Take off contaminated clothing and wash before reuse. In case of fire: Use water spray (fog), foam, dry powder or carbon dioxide for extinction. Dispose of contents/container to location in accordance with local/regional/national/international regulations.

This test is for in vitro diagnostic use only. The reagents are harmful if swallowed. Avoid contact with eyes and skin.

Keep the solution away from direct sunlight.

## Reagent Preparation and Storage

The reagents are ready-to-use, no additional preparation is required. All assay components, opened or unopened, are stable, until the expiration date indicated on their respective labels when stored at room temperature. Do not use the reagents beyond their expiration dates.

In the case of accidental spill, clean and dispose of material according to your laboratory's SOP, local, state, and country regulations.

In the case of damaged packaging on arrival, contact your technical support representative (contact details listed at the end of this package insert).

## Specimen Collection and Handling

Collect urine specimens in plastic or glass containers. "The Mandatory Guidelines for Federal Workplace Drug Testing Programs: Final Guidelines: Notice" recommends that specimens that do not receive an initial test within 7 days of arrival at the laboratory should be placed into secure refrigeration units. Handle all urine specimens as if they were potentially infectious.<sup>10</sup>

## Assay Procedure

Analyzers capable of maintaining a constant temperature, pipetting samples, mixing reagents, measuring absorbance at 340 nm and timing the reaction accurately can be used to perform this assay.

Before performing the assay, refer to the appropriate analyzer-specific protocol sheet, which contains parameters and/or additional instructions for use.

## Quality Control and Calibration

Good laboratory practice suggests the use of control specimens to validate the calibration and to ensure proper assay performance. The 1.015 g/mL and 1.030 g/mL specific gravity controls are available from Microgenics for this purpose. Ensure that control results are within established ranges as determined by your laboratory. Recalibrate the system when new reagents are used or when the control values are outside established ranges. Use both low and high specific gravity calibrators to generate the calibration curve. A typical calibration curve with a Hitachi 717 analyzer is as follows:

Calibrator	Absorbance (mA/min)
1.010	892
1.025	1208

All quality control requirements should be performed in conformance with local, state and/or federal regulations or accreditation requirements.

## Results and Data Interpretation

The specific gravity values of the calibrators and controls used in the Gravity-Detect Test are established and verified by a conventional gravimetric method. The sample specific gravity is extrapolated from the calibration curve using the absorbance value of the sample. Most clinical chemistry analyzers have built-in curve-fit software that can calculate the sample specific gravity values automatically with no additional requirement of data manipulation.

## Expected Values

The range of urine specific gravity of apparently healthy individuals has been determined to be 1.003 g/mL to 1.035 g/mL.<sup>2,3</sup> However, it is recommended that each laboratory establish its own normal urine specific gravity range. Urine samples with a low specific gravity may indicate dilution of the specimen. Urine samples with a high specific gravity may suggest the addition of salt or other adulterants.

## Limitations

This assay is optimized for the quantitative determination of specific gravity in human urine only. The reportable range is 1.000 g/mL to 1.040 g/mL. It is recommended that specific gravity values less than 1.000 g/mL be reported as "<1.000" and specific gravity values greater than 1.040 g/mL be reported as ">1.040".

### Typical Performance Characteristics

The following typical performance data were generated with a Hitachi 717 clinical chemistry analyzer:

#### Precision

Within-run and run-to-run precision were evaluated using clinical urine samples at various specific gravity levels. The following results were obtained:

Within-run (n=20)		Run-to-run (n=10)	
Mean (g/mL)	%CV	Mean (g/mL)	%CV
1.015	0.04	1.010	0.00
1.032	0.06	1.030	0.04
1.016	0.02	1.020	0.03
1.009	0.03	1.010	0.04
1.020	0.12	1.020	0.00

#### Interference by Urine pH

Potential interference of the assay due to the variation of pH was investigated. Specific gravity did not vary more than  $\pm 0.003$  g/mL over a pH range of 3 to 11.

#### Interference by Endogenous Substances

Interference by endogenous substances in urine was studied. No interference was observed when urine samples were spiked with endogenous substances up to the concentration indicated in the table below.

Interferant	Concentration	Interferant	Concentration
Albumin	500 mg/dL	Urea	6 mg/dL
Creatinine	500 mg/dL	Glucose	3 mg/dL
Galactose	10 mg/dL	Riboflavin	7.5 mg/dL
Hemoglobin	300 mg/dL	Ascorbic Acid	20 mg/dL

For information on substances or conditions that may affect the specific gravity values in vivo, refer to publications<sup>11,12</sup> in the Bibliography section.

#### Linearity

Solutions containing specific gravity levels at 1.006, 1.010, 1.015, 1.020, 1.025 and 1.030 g/mL were prepared and assayed with the test. A correlation coefficient of 0.999 was obtained when the absorbance value of each solution was plotted against its corresponding specific gravity value.

#### Accuracy and Correlation

The expected specific gravity of a series of urine samples was determined using the traditional weight by volume method. They were compared to the specific gravity determined by the Gravity-Detect Test. A recovery range of 99.6% to 100.3% was observed. Specific gravity of sixty-five clinical urine samples was determined with both Gravity-Detect and a commercially available method. The following linear regression analysis was observed:  $(y) = 0.98(x) + 0.02$ , with a correlation coefficient ( $r$ ) of 0.983. The sample mean specific gravity for the Gravity-Detect Test was 1.028 g/mL with a range of 1.004 to 1.062 g/mL. The sample mean specific gravity for the commercial method was 1.026 g/mL with a range of 1.004 to 1.048 g/mL.

### Bibliography

1. Mandatory Guidelines for Federal Workplace Drug Testing Programs. National Institute on Drug Abuse. Federal Register Vol. 53, No. 69, 11979 (1988).
2. Schumann GB, and Schweitzer SC, 1989, Examination of Urine. In Clinical Chemistry: Theory, Analysis and Correlation, 2nd Edition, Kaplan LA, and Pesce AJ (Eds.) pp 820-849.
3. Cody GT. Specimen Adulteration in Drug Urinalysis. Forensic Science Review. 2, 63 (1990).
4. Tietz, NW, ed. Clinical Guide to Laboratory Tests. Philadelphia: WB Saunders, 514 (1990).
5. Edwards C, Fyfe MJ, Liu RH and Walia AS. Evaluation of Common Urine Specimen Adulteration Indicators. J Anal Toxicol 17, 251 (1993).
6. Murray RL, 1989. Creatinine. In Clinical Chemistry: Theory, Analysis and Correlation, 2nd Edition, Kaplan LA and Pesce AJ (Eds.) pp 1015-1020.
7. Newkirk RE and Rawnsley HM, Creatinine Clearance, ASCP Check Sample Clinical Chemistry, No. CC-110, Chicago, 1978, American Society of Clinical Pathologists.
8. Faulkner WR and King JW, Renal Function. In Tietz NW, Ed. Fundamentals of Clinical Chemistry, 2nd Edition, Philadelphia, 1976, WB Saunders Co, pp 975-1014.
9. Law WT and G Ertingshausen, Novel Reagent and Method for Direct Determination of Chloride in Serum with a Centrifugal Analyzer. Clin. Chem 26, 1874-1877 (1980).
10. Centers for Disease Control/National Institutes of Health Manual Biosafety in Microbiological and Biomedical Laboratories. 1988.
11. Young DS. Effects of Drugs on Clinical Laboratory Tests. 3rd ed., Washington, DC: AACC Press; 1990.
12. Friedman RB and DS Young. Effects of Disease on Clinical Laboratory Tests. 2nd ed., Washington, DC: AACC Press; 1989.



Microgenics Corporation  
46500 Kato Road  
Fremont, CA 94538 USA  
US Customer and  
Technical Support:  
1-800-232-3342

EC REP

B-R-A-H-M-S GmbH  
Neuendorfstrasse 25  
16761 Hennigsdorf, Germany



For insert updates go to:  
[www.thermoscientific.com/diagnostics](http://www.thermoscientific.com/diagnostics)

#### Other countries:

Please contact your Thermo Fisher Scientific representative.

1208-9-EN  
2017 08

**Thermo**  
SCIENTIFIC